GlassScriptPhysician profile
Brooke H Weidig
NPI 1386691905
$5,797.09
in general payments reported to CMS, 2019-2025
39 companies · $2,529 in 2025
The $2,529 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $970 · 2022: $685 · 2023: $616 · 2024: $996 · 2025: $2,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,965 · Travel and Lodging: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.31 |
| Travel and Lodging | $1,175.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $1,664.34 | 2025 | |
| Lilly USA, LLC | $490.02 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $442.26 | 2023-2025 | |
| Novo Nordisk INC | $418.59 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $344.41 | 2021-2024 | |
| Glaxosmithkline, LLC. | $291.54 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.75 | 2021-2025 | Synjardy, Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.22 | 2021-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $179.37 | 2021-2025 | Veozah |
| Antares Pharma, INC. | $161.13 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Optinose US, INC. | $140.19 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $118.44 | 2022 | |
| Idorsia Pharmaceuticals US INC | $96.97 | 2023-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $80.18 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $78.72 | 2021-2023 | Trintellix |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Weidig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.